Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the greatest life threats for Chinese people, and the prognosis of this malignancy is poor due to the strong chemotherapy resistance in patients. Notch pathway components mediate cell survival and epithelial–mesenchymal transition (EMT), and also participate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yingshi, Li, Dandan, Jiang, Qiyu, Cao, Shuang, Sun, Huiwei, Chai, Yantao, Li, Xiaojuan, Ren, Tianshu, Yang, Ruichuang, Feng, Fan, Li, Bo-an, Zhao, Qingchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030059/
https://www.ncbi.nlm.nih.gov/pubmed/29970890
http://dx.doi.org/10.1038/s41419-018-0804-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030059/
https://www.ncbi.nlm.nih.gov/pubmed/29970890
http://dx.doi.org/10.1038/s41419-018-0804-6

Ejemplares similares